Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. LivaNova PLC
  6. Summary
    LIVN   GB00BYMT0J19

LIVANOVA PLC

(LIVN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/13/2021 10/14/2021 10/15/2021 10/18/2021 10/19/2021 Date
82.31(c) 83.87(c) 83.89(c) 82.37(c) 82.58 Last
138 917 245 485 320 169 428 839 128 305 Volume
+1.12% +1.90% +0.02% -1.81% +0.25% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 017 M - -
Net income 2021 -85,7 M - -
Net Debt 2021 228 M - -
P/E ratio 2021 -51,2x
Yield 2021 -
Sales 2022 1 048 M - -
Net income 2022 41,5 M - -
Net Debt 2022 116 M - -
P/E ratio 2022 90,3x
Yield 2022 -
Capitalization 4 394 M 4 394 M -
EV / Sales 2021 4,55x
EV / Sales 2022 4,30x
Nbr of Employees 4 000
Free-Float 98,6%
More Financials
Company
LivaNova PLC is a medical device company. The Company is focused on the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems throughout the world. The Company operates through two segments: Cardiac Surgery and Neuromodulation. Its Cardiac Surgery Business Franchise (CS) is engaged in the development, production and sale of cardiac surgery... 
More about the company
Ratings of LivaNova PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about LIVANOVA PLC
10/04LIVANOVA : to Host Conference Call for Third Quarter 2021 Results
BU
09/14LIVANOVA : Helius Medical Technologies, Inc. Appoints Paul Buckman to its Board of Directo..
AQ
08/26LIVANOVA : to Present at the Baird 2021 Global Healthcare Conference
BU
08/20LIVANOVA : Needham Adds Buy-Rated LivaNova to Conviction List on Debt Repayment, Anticipat..
MT
08/17LIVANOVA : Baird Adjusts LivaNova's Price Target to $105 From $100, Keeps Outperform Ratin..
MT
08/16LIVANOVA : Lifts Full-Year Adjusted EPS Guidance Amid Term Loan Early Retirement, Revolvin..
MT
08/16LIVANOVA : Announces Early Retirement of $450 Million Term Loan and Executes $125 Million ..
PU
08/16LIVANOVA PLC : Entry into a Material Definitive Agreement, Termination of a Material Defin..
AQ
08/16LIVANOVA : Announces Early Retirement of $450 Million Term Loan and Executes $125 Million ..
BU
08/16LivaNova Announces Early Retirement of $450 Million Term Loan and Executes $125 Million..
CI
08/06LIVANOVA PLC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/04LIVANOVA : Prices Offering at $82.50 Per Share
MT
08/03LIVANOVA : Prices Offering of Ordinary Shares
BU
08/03UPDATE : LivaNova Shares Fall Following Launch of $300 Million Share Offering
MT
08/03LIVANOVA : Announces Offering of Ordinary Shares (Form 8-K)
PU
More news
News in other languages on LIVANOVA PLC
06/02LIVANOVA : vollzieht den initialen Verkaufsabschluss des Herzklappengeschäfts an Gyrus Cap..
06/01LIVANOVA : conclut la clôture initiale de l'activité relative aux valves cardiaques avec G..
06/01LIVANOVA : completa il closing iniziale della cessione del Business delle Valvole cardiach..
2020LIVANOVA : und Gyrus Capital schließen Vereinbarung über den Kauf des Herzklappengeschäfts
2020LIVANOVA : e Gyrus Capital stipulano un accordo per l'acquisto del business delle valvole ..
More news
Analyst Recommendations on LIVANOVA PLC
More recommendations
Chart LIVANOVA PLC
Duration : Period :
LivaNova PLC Technical Analysis Chart | LIVN | GB00BYMT0J19 | MarketScreener
Technical analysis trends LIVANOVA PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 82,58 $
Average target price 97,13 $
Spread / Average Target 17,6%
EPS Revisions
Managers and Directors
Damien McDonald Chief Executive Officer & Executive Director
Alex Shvartsburg Chief Financial Officer
William A. Kozy Non-Executive Chairman
Marco Dolci Head-Global Operations, R&D
Daniel Jeffrey Moore Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LIVANOVA PLC24.41%4 383
ABBOTT LABORATORIES6.69%207 101
MEDTRONIC PLC3.06%162 466
BECTON, DICKINSON AND COMPANY-4.70%68 480
HOYA CORPORATION23.83%54 729
DEXCOM, INC.46.40%52 368